Common painkiller could boost immunotherapy in advanced lung cancer
NCT ID NCT06731270
First seen Feb 17, 2026 · Last updated Jun 19, 2026 · Updated 19 times
Summary
This phase II trial tests whether adding diclofenac, a common anti-inflammatory painkiller, can help control advanced non-small cell lung cancer when immunotherapy alone starts to show signs of failing. About 20 adults whose cancer has progressed while on standard immunotherapy drugs like pembrolizumab or atezolizumab will receive diclofenac alongside their current treatment. The goal is to see if this combination can shrink tumors or slow the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University Hospital Midtown
RECRUITINGAtlanta, Georgia, 30308, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
diclofenac
What this could lead to
If it works, this could offer a way to extend the benefit of immunotherapy for people with advanced lung cancer, potentially delaying disease progression.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply broadly. Diclofenac also has known risks like stomach bleeding and kidney issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.